Press Releases

Press Releases

Samsung Biologics awarded Leadership status by CDP for climate action efforts

Samsung Biologics awarded Leadership status by CDP for climate action efforts


- Samsung Biologics placed in leadership band with A- grade

- Leadership status recognition of implementing current best practices


Incheon, S. Korea, February 13, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).

The leadership rating is a recognition of the company’s ongoing efforts to mitigate the risks of climate change and implementation of the current best practices. The CDP, a non-profit organization that annually evaluates corporate environmental transparency, disclosed over 23,000 companies worldwide across 17 categories, including governance, risk management processes, business strategy and opportunity disclosure. Samsung Biologics was granted Management status and B rating in 2022.


“The leadership status reflects our progress in sustainability management and collaborative efforts to decarbonize across the supply chain,” said John Rim, CEO and President of Samsung Biologics. “We will continue our environmental stewardship as we implement better services and practices along with our clients and suppliers to mitigate climate risks and build a healthier future.”


Samsung Biologics has been bolstering sustainable operations and accelerating the transition to renewable energy by utilizing low-carbon technologies, such as ultra-low NOx burners, solar panels, and energy monitoring systems. The company is also an active member of the Sustainable Markets Initiative and supports various global initiatives, including the United Nations Global Compact and RE100. Last month, Samsung Biologics received the Platinum Sustainability Rating from EcoVadis, the highest rank given, for its sustainability performance.

Samsung Biologics awarded Leadership status by CDP for climate action efforts


- Samsung Biologics placed in leadership band with A- grade

- Leadership status recognition of implementing current best practices


Incheon, S. Korea, February 13, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).

The leadership rating is a recognition of the company’s ongoing efforts to mitigate the risks of climate change and implementation of the current best practices. The CDP, a non-profit organization that annually evaluates corporate environmental transparency, disclosed over 23,000 companies worldwide across 17 categories, including governance, risk management processes, business strategy and opportunity disclosure. Samsung Biologics was granted Management status and B rating in 2022.


“The leadership status reflects our progress in sustainability management and collaborative efforts to decarbonize across the supply chain,” said John Rim, CEO and President of Samsung Biologics. “We will continue our environmental stewardship as we implement better services and practices along with our clients and suppliers to mitigate climate risks and build a healthier future.”


Samsung Biologics has been bolstering sustainable operations and accelerating the transition to renewable energy by utilizing low-carbon technologies, such as ultra-low NOx burners, solar panels, and energy monitoring systems. The company is also an active member of the Sustainable Markets Initiative and supports various global initiatives, including the United Nations Global Compact and RE100. Last month, Samsung Biologics received the Platinum Sustainability Rating from EcoVadis, the highest rank given, for its sustainability performance.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION